Mesoblast is an Australian regenerative-medicine company developing allogeneic cell therapies based on mesenchymal lineage cells. Its product Ryoncil (remestemcel-L) is the first FDA-approved mesenchymal stromal cell therapy, indicated for steroid-refractory acute graft-versus-host disease in pediatric patients. The broader pipeline targets inflammatory and degenerative conditions such as heart failure and chronic low back pain related to disc disease.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2023 | 7.5 | — | -81.9 | — |
| 2024 | 5.9 | -21.3% | -88 | — |
| 2025 | 17.2 | 191.4% | -102.1 | — |
| 2026 | 120.3 | 599.2% | -57.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: S&T Bancorp, Inc. (STBA), Alignment Healthcare, Inc. (ALHC), Hope Bancorp, Inc. (HOPE), Nayax Ltd. (NYAX), DENTSPLY SIRONA Inc. (XRAY), PicS N.V. (PICS)